Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.mankindpharma.com | |
Market Cap | 77,121.29 Cr. | |
Enterprise Value(EV) | 75,079.60 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 32.00 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 60.16 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 38.68 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 210.40 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 9.15 | Calculated using Price: 1,925.20 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 40.06 Cr. | 400,588,440 Shares |
FaceValue | 1 | |
About Mankind Pharma Ltd. | ||
The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. |
1 Day |
|
+1.45% |
1 Week |
|
-0.46% |
1 Month |
|
+9.83% |
3 Month |
|
+8.15% |
6 Month |
|
+41.97% |
1 Year |
|
|
2 Year |
|
|
5 Year |
|
|
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 21.61 | 25.06 | 24.28 | 23.69 | 21.06 | 33.12 | 31.51 | 26.72 | 19.27 | |
Return on Capital Employed (%) | 30.32 | 36.47 | 35.49 | 33.47 | 28.49 | 43.22 | 39.97 | 33.96 | 23.49 | |
Return on Assets (%) | 17.54 | 20.08 | 19.10 | 16.98 | 14.22 | 22.94 | 22.79 | 18.83 | 13.94 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 2,055 | 2,257 | 2,927 | 2,881 | 2,823 | 3,485 | 4,722 | 6,155 | 7,435 | 8,428 | |
Non Curr. Liab. | 28 | 34 | 53 | 49 | 78 | 103 | 107 | 169 | 199 | 236 | |
Curr. Liab. | 433 | 528 | 663 | 1,296 | 1,024 | 1,251 | 1,353 | 2,623 | 1,863 | 2,128 | |
Minority Int. | 16 | 29 | 98 | 134 | 159 | 186 | 141 | 161 | 188 | 205 | |
Equity & Liab. | 2,532 | 2,848 | 3,741 | 4,360 | 4,084 | 5,025 | 6,324 | 9,108 | 9,686 | 10,998 | |
Non Curr. Assets | 859 | 1,142 | 1,672 | 1,787 | 2,085 | 2,206 | 2,417 | 4,702 | 5,358 | 5,335 | |
Curr. Assets | 1,673 | 1,707 | 2,069 | 2,574 | 1,998 | 2,820 | 3,907 | 4,404 | 4,325 | 5,662 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2,532 | 2,848 | 3,741 | 4,360 | 4,084 | 5,025 | 6,324 | 9,108 | 9,686 | 10,998 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 3,323 | 3,944 | 4,382 | 4,949 | 4,980 | 5,872 | 6,214 | 7,782 | 8,749 | |
Other Income | 76 | 71 | 108 | 72 | 53 | 104 | 171 | 196 | 129 | |
Total Income | 3,399 | 4,015 | 4,490 | 5,021 | 5,033 | 5,976 | 6,385 | 7,978 | 8,878 | |
Total Expenditure | -2,738 | -3,185 | -3,536 | -3,933 | -4,055 | -4,427 | -4,565 | -5,791 | -6,848 | |
PBIDT | 662 | 830 | 953 | 1,088 | 978 | 1,549 | 1,820 | 2,187 | 2,031 | |
Interest | -2 | -3 | -4 | -25 | -44 | -23 | -21 | -60 | -46 | |
Depreciation | -39 | -43 | -31 | -46 | -69 | -99 | -119 | -167 | -326 | |
Taxation | -177 | -244 | -290 | -329 | -264 | -382 | -399 | -522 | -362 | |
Exceptional Items | ||||||||||
PAT | 444 | 540 | 629 | 688 | 601 | 1,045 | 1,293 | 1,453 | 1,310 | |
Minority Interest | -6 | -28 | -32 | -26 | -28 | -19 | -28 | |||
Share Associate | 1 | 2 | 0 | -3 | 10 | 12 | ||||
Other Related Items | ||||||||||
Consolidated Net Profit | 439 | 542 | 629 | 656 | 579 | 1,030 | 1,265 | 1,433 | 1,282 | |
Adjusted EPS | 11 | 14 | 16 | 16 | 14 | 26 | 32 | 36 | 32 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 280 | 537 | 628 | 639 | 600 | 1,072 | 1,137 | 920 | 1,813 | |
Cash Fr. Inv. | -348 | -152 | -625 | -505 | -444 | -439 | -1,222 | -1,369 | -1,054 | |
Cash Fr. Finan. | 9 | -361 | 2 | -89 | -175 | -527 | -8 | 605 | -740 | |
Net Change | -59 | 25 | 5 | 46 | -19 | 106 | -93 | 155 | 19 | |
Cash & Cash Eqvt | 39 | 78 | 87 | 135 | 116 | 226 | 127 | 283 | 305 |
Thu, 30 Nov 2023
Analysts/Institutional Investor Meet/Con. Call Updates
|
|
Tue, 28 Nov 2023
Updates
|
|
Wed, 22 Nov 2023
Analysts/Institutional Investor Meet/Con. Call Updates
|
Thu, 30 Nov 2023 |
|
|
|
|
|